High Impact Relationships Accelerate Results
In medicine, we know that successful treatment regimens require an understanding of how to develop and deploy the right drug or drug combination at the right time. That’s why Exelixis has a long history of leveraging productive partnerships and collaborations to move our molecules and our business forward. Our model for value creation is built upon a disciplined use of resources and a vast oncology clinical development and commercialization network. Our strategy is enhanced by our history of prolific drug discovery, aptitude for recognizing the missed potential of validated targets and ability to focus on oncology assets that are asymmetrically valued or misunderstood. With a focused, nimble team, we fully commit to our programs and partnerships.
Today, we’re oriented around three types of collaborative relationships:
Maximizing the opportunities for our flagship product, cabozantinib: We have an extensive, long-term pipeline strategy for cabozantinib and are focused on optimizing the molecule through broad clinical development. With the support of our partners at Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Ltd. (Takeda), for example, we are able to significantly increase the scope of our clinical development program and ultimately expand the global footprint of cabozantinib. With Bristol-Myers Squibb Company (BMS) and Genentech, Inc. (a member of the Roche Group) (Genentech), we are evaluating cabozantinib’s potential to become the small molecule of choice to combine with leading checkpoint inhibitors (CPIs).
Exelixis discoveries moving forward in the hands of partners: Our history of productive drug discovery includes partnering multiple compounds and programs with leading pharmaceutical and biopharmaceutical companies such as BMS, Daiichi Sankyo Company Limited (Daiichi Sankyo), Genentech, Merck (known as MSD outside of the United States and Canada) and Sanofi. These relationships include opportunities in cancer, inflammation, and cardiovascular and metabolic diseases. As these partnered programs advance, they have the potential to generate revenues that can support our own internal discovery efforts.
Working together to identify the next generation of Exelixis medicines: In addition to conducting its own internal drug discovery activities, Exelixis is actively seeking in-licensing or acquisition opportunities to bring promising product candidates or other assets into its pipeline. In January and May 2018, Exelixis entered into collaborations with StemSynergy Therapeutics, Inc. (StemSynergy) and Invenra, Inc. (Invenra), respectively. StemSynergy is working with Exelixis on the discovery and development of novel oncology compounds targeting Casein Kinase 1 alpha. Invenra and Exelixis are partnering to discover and develop multispecific antibodies for the treatment of cancer, complementing Exelixis’ in-house small molecule drug discovery efforts. In May 2019, Exelixis entered into an exclusive partnership with Iconic Therapeutics, Inc. to advance an innovative next-generation antibody-drug conjugate program for cancer.